JPRN-UMIN000023039招募中未知
Multicenter Clinical Performance Study to evaluate Plasma-based RAS Gene Mutation Testing using OncoBEAM RAS CRC assay (LS52R) of Patients having Progressive or Recurrent Colorectal Cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Patients with pathologically confirmed primary colorectal adenocarcinoma
- •2)Patients aged 20 or older at the time of the informed consent
- •3)Patients who signed informed consent form
- •4)Patients whose blood collection is possible before a treatment start
- •5)Patients confirmed Stage4 colorectal cancer by imaging findings
- •6)Patients with no previous chemotherapy, or patients whose PD or clinical PD was confirmed before starting next treatment
排除标准
- •1)Patients judged ineligible to participate in the study
- •2)Patients registered to the study in the past
- •3)Patients with a history of multiple cancer or with a comorbid multiple cancer
- •4)Patients with synchronous or metachronous (a disease-free interval of five years or shorter) double cancer
- •5)Patients with histories of treatment using drugs targeting EGFR such as an anti-EGFR antibody or Regorafenib
研究者
相似试验
招募中
不适用
To assess the efficacy (survivorship) of the Quadra-P Hydroxyapatite coated femoral stem in patients undergoing a primary total hip replacement surgery.Hip OsteoathritisMusculoskeletal - OsteoarthritisACTRN12620000441910Medacta Australia Pty Ltd300
已完成
不适用
A Multicenter Clinical Evaluation Study to Determine the External Site Accuracy of Total Immunoglobulin E Measurement using a Novel Point-of-Care Test Device Compared to a Reference Method in Atopic Subjectsatopic asthma10006436allergic asthmaNL-OMON44019ovartis30
已完成
不适用
Multi-Centre Trial to Evaluate the Clinical Performance of the Lifetech/Medtronic Ceraflex-ASD-Occluder for Transcatheter Closure of Secundum Atrial Septal DefectsAtrial septal defectQ21.1DRKS00010233Deutsches Herzzentrum München149
已完成
4 期
To study the safety and efficacy of Ranibizumab of Intas Pharmaceuticals Ltd. in patients with visual impairment.CTRI/2016/03/006739Intas Pharmaceuticals Ltd126
已完成
不适用
Reduction of contrast induced nephropathy (CIN) in patients requiring a percutaneous coronary intervention procedure and have chronic renal failure.Cardiovascular disease in patients with chronic kidney disease.Renal and Urogenital - Kidney diseaseCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12612000238875Osprey Medical Pty Ltd42